Literature DB >> 34866036

Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53.

Stephen L Abrams1, Shaw M Akula1, Linda S Steelman1, Matilde L Follo2, Lucio Cocco2, Stefano Ratti2, Alberto M Martelli2, Massimo Libra3, Luca Falzone3, Saverio Candido3, Giuseppe Montalto4, Melchiorre Cervello5, Paolo Lombardi6, James A McCubrey7.   

Abstract

Approaches to improve pancreatic cancer therapy are essential as this disease has a very bleak outcome. Approximately 80% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC). A key regulatory gene frequently mutated (∼75%) in PDAC is the TP53 tumor suppressor gene which controls the transcription of multiple genes involved in cell cycle progression, apoptosis, cancer progression and other growth regulatory processes. The mouse double minute 2 homolog (MDM2) gene product is a nuclear-localized E3 ubiquitin ligase and negatively regulates the TP53 protein which results in its proteasomal degradation. Various MDM2 inhibitors have been isolated and examined in clinical trials, especially in patients with hematological malignancies. Nutlin-3a is one of the first MDM2 inhibitors isolated. Berberine (BBR) is a natural product found in many fruits and berries and used in traditional medicine for centuries. It has many biological effects, and some are anti-proliferative in nature. BBR may activate the expression of TP53 and inhibit cell cycle progression as well as other events important in cell growth. To understand more about the potential of compounds like BBR and chemical modified BBRs (NAX compounds) to sensitize PDAC cells to MDM2 inhibitors, we introduced either WT-TP53 or the pLXSN empty vector control into two PDAC cell lines, one lacking expression of TP53 (PANC-28) and one with gain-of-function mutant TP53 on both alleles (MIA-PaCa-2). Our results indicate that nutlin-3a was able to increase the sensitivity to BBR and certain NAX compounds. The effects of nutlin-3a were usually more substantial in those cells containing an introduced WT TP53 gene. These results highlight the importance of knowledge of the type of TP53 mutation that is present in cancer patients before the administration of drugs which function by stabilization of the TP53 protein.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Berberine; NAX compounds; Nutlin-3a; PDAC; TP53; Targeted therapy

Mesh:

Substances:

Year:  2021        PMID: 34866036     DOI: 10.1016/j.jbior.2021.100840

Source DB:  PubMed          Journal:  Adv Biol Regul        ISSN: 2212-4926


  2 in total

1.  APR-246-The Mutant TP53 Reactivator-Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells.

Authors:  James Andrew McCubrey; Stephen L Abrams; Linda S Steelman; Lucio Cocco; Stefano Ratti; Alberto M Martelli; Paolo Lombardi; Agnieszka Gizak; Przemysław Duda
Journal:  Biomolecules       Date:  2022-02-08

Review 2.  Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression.

Authors:  James A McCubrey; Li V Yang; Stephen L Abrams; Linda S Steelman; Matilde Y Follo; Lucio Cocco; Stefano Ratti; Alberto M Martelli; Giuseppa Augello; Melchiorre Cervello
Journal:  Cells       Date:  2022-07-09       Impact factor: 7.666

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.